RUNX1 Inhibition Using Lipid Nanoparticle-Mediated Silencing RNA Delivery as an Effective Treatment for Acute Leukemias

RUNX1 is one of three mammalian RUNX members, along with RUNX2 and RUNX3. RUNX1 contains a conserved Runt domain that mediates DNA binding and heterodimerization to their partner protein CBFB. RUNX1 and CBFB form a complex that regulates hematopoietic gene expression [1 –3]. Disruption of RUNX1 has been implicated in the development of hematopoietic neoplasms. Chromosomal abnormalities involving the RUNX1 gene are associated with several types of leukemia, including acute myeloid leukemia (AML) driven by RUNX1–RUNX1T1 [4,5].

Source: Experimental Hematology - May 25, 2022 Category: Hematology Authors: Kohei Iida, Akiho Tsuchiya, Moe Tamura, Keita Yamamoto, Shigehisa Kawata, Mitsuko Ishihara-Sugano, Motohiro Kato, Toshio Kitamura, Susumu Goyama Tags: Brief Communication Source Type: research